Back in May, Johnson & Johnson's Janssen and California-based Aduro Biotech inked a $365 million deal centered on the former's vaccine technology as a treatment for prostate cancer. But J&J is convinced Aduro's platform has the potential to bolster its oncology pipeline in other areas, too.
A banner year for Berkeley, CA-based Aduro just got better. The biotech has inked its second licensing pact of the year with Johnson & Johnson, which kicked in a $30 million upfront and boosted its total milestone package to the $1 billion-plus category.
Johnson & Johnson provided a first glimpse of what its devices and diagnostics business will look like after the divestiture of the Ortho Clinical Diagnostics business. The conglomerate gained about $1.1 billion from its sale, which closed on June 30. Excluding the operational impact, the Ortho-Clinical deal boosted sales growth figures for the device and diagnostics unit, as well as the company overall.
Alarmed payers are gearing up for another hepatitis C battle. Now that Gilead Sciences' new two-in-one infection fighter Harvoni is approved--and with a $94,500 price--it's worth looking at some strategies payers have used with other hep C drugs, including Sovaldi, the single-agent sibling to Harvoni.
Johnson & Johnson is riding the tailwinds of recent success, celebrating positive third quarter earnings buoyed by record-setting sales of its top products and the sell-off of its Ortho-Clinical Diagnostics business.
The Sunshine Act data's been out in the open for a couple of days now (well--most of it), and despite the database's clunkiness, the number crunching is well underway. The Wall Street Journal, for one, has broken down which pharma companies topped the doc-paying list in a variety of different spending categories.
Johnson & Johnson is taking a deep dive into antivirals, trading $1.75 billion for private biotech Alios BioPharma to get its hands on a midstage treatment and some early assets that could expand its share of the blockbuster hepatitis C market.
Johnson & Johnson pessimists are already worried that Olysio will have a short, happy, busy life and an all-too-sudden end.
Johnson & Johnson pessimists are already worried that Olysio will end up like a mayfly, with a short, happy, busy life and an all-too-sudden end. If the U.K.'s cost-effectiveness gatekeepers offer any indication, they may be correct.
Even drugmakers with steamrolling pharma units need to cut costs sometimes, and Johnson & Johnson fits that bill. To do so, the company will shrink the pension benefits offered to those who are hired--or rehired--after January 1.